PRESS RELEASE - August 3, 2007
CAVIT SCIENCES, INC. ANNOUNCES ADDITIONAL COMPOUND INFORMATION
Contact: Colm King
561-544 6988
info@cavitsciences.com
www.CavitSciences.com
Delray Beach, FL, August 3, 2007—Cavit Sciences, Inc. (“Cavit”) (OTCBB: CVIT) today announced the synergism of its compounds in treating and preventing degenerative diseases.
On June 14, 2007, Cavit announced testing results of its leading product candidate, CT-5, in treating cancer and viral infections. Indications include inhibition of virus replication, inhibition of metastasis of melanoma, suppression of tumor metastasis, potent activity against tumor growth and significantly increased survival rates of subjects. Trials have shown that the drug is well tolerated and have demonstrated its safety.
On July 12, 2007, Cavit announced the filing of its continuation-in-part applications, which included 19 additional compounds and numerous additional indications including the treatment of opportunistic infections and increasing the efficiency of the immune system.
The 19 additional compounds consist of natural extracts, synthetic organic products, whole cell preparations, polysaccharides, acids, antibiotics, biological-response-modifiers and traditional herbal medicines. Administered independently or employed with other therapies, these compounds have achieved the proven results listed below:
1) Act as biological-response-modifiers (“BRM”). BRM’s are substances that can enable the body to change its response to tumors, resulting in therapeutic benefits. They do not directly attack cancer and viral cells; instead, they stimulate the body’s immune system, making it potentially effective in the treatment of cancer as well as other degenerative diseases.
2) Stimulate the production of interferon. Interferon’s most important function is to augment and stimulate the body’s production of natural killer (“NK”) cells, which directly combat cancer cells. Interferon plays an important part in our immune system, and is recognized as a powerful anticancer agent.
3) Enhance the immune system and restore previously impaired immune response, making patients less susceptible to certain infections. Beneficial effects on the maintenance of the patients’ immune status and general health.
4) Immunomodulators for control of infections with various immunomodulatory activities.
5) Therapeutic activity against opportunistic infections.
6) Inhibition of tumor growth, a decrease in metastasis and prolonged survival times.
7) Antiviral activities, anti-bacterial activities, anti-inflammatory activities and immunopotentiating activities.
8) Immuno-restorative effect in those people receiving radiation treatment after surgery and increase in white blood cell count.
9) Relief of pain associated with various human malignancies.
Research suggests that the conjugation, combination or employing certain of the above compounds in conjunction with other traditional therapies could aggressively treat various cancers, bacterial infections, viral infections and related diseases. Various combinations of the above compounds may possibly exert a synergistic effect on certain indications. The underlying principle of Cavit’s combination therapy is to improve the resistance of the patients through the pharmaceutical action of these compounds or to restore the patient to a normal physiological state.
We are working towards the goal of having treatments available to patients and individuals for the prevention and treatment of diseases in the U.S. and worldwide in a rapid and cost-effective manner.
Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. Cavit’s drugs have not been evaluated by the Food and Drug Administration and the efficacy of these drugs has not been confirmed by FDA-approved research. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by Cavit. These factors include, but are not limited to: (i) the ability of Cavit to successfully raise financing, (ii) the ability of Cavit to finalize its manufacturing and distribution facilities, and (iii) the ability of Cavit to successfully commercialize its products in certain markets. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Cavit’s filings with the Securities and Exchange Commission, including those factors discussed under the caption \"Risk Factors\" for Cavit on Form 10K-SB filed on April 12, 2007.
For additional information about this udpate, please visit www.CavitSciences.com.
About Cavit Sciences - Cavit Sciences, Inc. (“Cavit”) is a biotechnology company that has three developed supplement lines with products that enhance, improve, maintain and support the body by beneficially affecting various conditions and is engaged in developing treatments and prevention for cancer, viral infections, opportunistic infections, related diseases and the immune system. New product information and updates will continue to be added to Cavit’s website.
- END -
© 2007 Cavit Sciences
